Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study.
OBJECTIVE
To investigate the use of anecortave acetate, a new angiostatic cortisene, for the treatment of the leakage and/or neovascularization associated with idiopathic perifoveal telangiectasia (IPT) in an open label prospective pilot study.


METHODS
Seven eyes of six patients were treated with posterior juxtascleral administration of anecortave acetate delivered adjacent to the macula using a specially designed curved cannula. A full clinical examination and fluorescein angiography were performed at baseline and at 3-month intervals. The primary efficacy outcome for this pilot study was the mean change in visual acuity (Early Treatment Diabetic Retinopathy Study) from baseline.


RESULTS
The visual acuity remained unchanged in two eyes of two patients with nonproliferative disease after 24 months. The five eyes of four patients presenting with subretinal neovascularization, the proliferative stage of IPT, showed stabilization or improvement of lesion size, resolution of leakage, and stabilization of vision at last follow-up.


CONCLUSIONS
The results of this study suggest that anecortave acetate may inhibit retinal and subretinal permeability as well as neovascular proliferation in patients with IPT. A larger study accordingly should be designed in the future to evaluate the effectiveness and treatment of IPT with this drug.
Eandi
Chiara M
CM
The LuEsther T. Mertz Retina Research Center of Manhattan Eye, Ear and Throat Hospital, New York, New York 10021, USA.
Ober
Michael D
MD
Freund
K Bailey
KB
Klais
Christina M
CM
Slakter
Jason S
JS
Sorenson
John A
JA
Yannuzzi
Lawrence A
LA
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002199:Capillary Permeability; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011244:Pregnadienediols / Q000627:therapeutic use*; D011446:Prospective Studies; D015861:Retinal Neovascularization / Q000188:drug therapy*; D012171:Retinal Vessels / Q000187:drug effects*; D013684:Telangiectasis / Q000188:drug therapy*; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D011244:Pregnadienediols; C418047:anecortave acetate